

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Telix Pharmaceuticals Limited
ABN	85 616 620 369

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Christian Behrenbruch
Date of last notice	7 November 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	16 March 2026
No. of securities held prior to change	<p>Direct Interest</p> <ul style="list-style-type: none"> • 553,298 fully paid ordinary shares (including 400,000 American Depository Shares (each representing 1 ordinary share) in Telix Pharmaceuticals Limited). • 100,708 share options with an exercise price of \$4.38 per option and an expiry date of 26 January 2026. Options vest upon achievement of \$100M in cumulative revenue from product sales. Options allotted following shareholder approval at the AGM held 12 May 2021 (TLX009 - TLXAL). • 93,114 Performance Share Appreciation Rights (PSARs) (notional exercise price \$4.95) (TLX012 - TLXAO) issued following shareholder approval at the AGM held 18 May 2022.

See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

	<ul style="list-style-type: none"> • 120,268 PSARs (notional exercise price \$6.90) (TLX0015 - TLXAO) issued following shareholder approval at the AGM held 24 May 2023. • 144,037 PSARs (notional exercise price \$11.94) (TLX0024 - TLXAO) issued following shareholder approval at the AGM held 22 May 2024. • 166,483 PSARs (notional exercise price \$28.67) (TLX0030 - TLXAO) issued following shareholder approval at the AGM held 21 May 2025. • 2,595 Share Rights (SRs) (Nil exercise price) (TLX0031 - TLXAU) issued following shareholder approval at the AGM held 21 May 2025. <p>Indirect interest</p> <ul style="list-style-type: none"> • 20,675,000 fully paid ordinary shares (Elk River Holdings Pty Ltd as Trustee for The Behrenbruch Family Trust).
Class	Performance Share Appreciation Rights (TLX0015 – TLXAO)
Number acquired	Nil
Number disposed	20,045
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	<p>Direct Interest</p> <ul style="list-style-type: none"> • 654,006 fully paid ordinary shares (including 400,000 American Depository Shares (each representing 1 ordinary share) in Telix Pharmaceuticals Limited). • 93,114 PSARs (notional exercise price \$4.95) (TLX0012 - TLXAO) issued following shareholder approval at the AGM held 18 May 2022. • 100,223 PSARs (notional exercise price \$6.90) (TLX0015 - TLXAO) issued following shareholder approval at the AGM held 24 May 2023. • 144,037 PSARs (notional exercise price \$11.94) (TLX0024 - TLXAO) issued following shareholder approval at the AGM held 22 May 2024. • 166,483 PSARs (notional exercise price \$28.67) (TLX0030 - TLXAO) issued following shareholder approval at the AGM held 21 May 2025. • 2,595 SRs (Nil exercise price) (TLX0031 - TLXAU) issued following shareholder approval at the AGM held 21 May 2025. <p>Indirect interest</p> <ul style="list-style-type: none"> • 20,675,000 fully paid ordinary shares (Elk River Holdings Pty Ltd as Trustee for The Behrenbruch Family Trust).

See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>120,268 PSARs (TLXO015 – TLXAO) were granted to Dr Behrenbruch at the maximum possible outcome of 150% of target following shareholder approval at the AGM held 24 May 2023. At testing, following the conclusion of the performance period, the Board approved a vesting outcome of 125% of target (100,223 PSARs with an expiry date of two years from vesting), with the remaining 25% lapsed (20,045 PSARs). Refer to the Remuneration report within Telix's 2025 Annual report at https://ir.telixpharma.com/financial-information/annual-reports</p>
---	---

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

3 – ⁺Closed period Part

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

See chapter 19 for defined terms.